Bruker Corporation (NASDAQ:BRKR) Receives Consensus Recommendation of “Hold” from Analysts

Bruker Corporation (NASDAQ:BRKR) has received a consensus recommendation of “Hold” from the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $51.00.

A number of research analysts recently issued reports on BRKR shares. Bank of America dropped their price objective on shares of Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Saturday, September 27th. Wells Fargo & Company decreased their price objective on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Tuesday, August 5th. Citigroup lowered their price objective on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research report on Monday, August 4th. Finally, Jefferies Financial Group set a $60.00 target price on Bruker and gave the stock a “buy” rating in a research note on Monday, August 4th.

Bruker Stock Performance

Bruker stock opened at $36.98 on Monday. The stock has a market cap of $5.61 billion, a PE ratio of 71.12, a P/E/G ratio of 4.84 and a beta of 1.20. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The business’s 50-day moving average price is $33.51 and its two-hundred day moving average price is $37.52. Bruker has a 12-month low of $28.53 and a 12-month high of $67.42.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same quarter in the prior year, the business earned $0.52 EPS. The business’s quarterly revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, analysts expect that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd were given a $0.05 dividend. The ex-dividend date of this dividend was Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is presently 38.46%.

Insider Buying and Selling at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the transaction, the director owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

A number of hedge funds have recently made changes to their positions in BRKR. Thrivent Financial for Lutherans lifted its stake in Bruker by 11.9% in the second quarter. Thrivent Financial for Lutherans now owns 29,032 shares of the medical research company’s stock valued at $1,196,000 after purchasing an additional 3,085 shares during the last quarter. Advisory Services Network LLC lifted its position in shares of Bruker by 35.9% during the 2nd quarter. Advisory Services Network LLC now owns 9,535 shares of the medical research company’s stock valued at $366,000 after buying an additional 2,520 shares during the last quarter. FORA Capital LLC grew its stake in shares of Bruker by 94.1% during the 2nd quarter. FORA Capital LLC now owns 21,239 shares of the medical research company’s stock worth $875,000 after acquiring an additional 10,294 shares during the period. Tower Research Capital LLC TRC increased its holdings in Bruker by 56.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock worth $172,000 after acquiring an additional 1,497 shares during the last quarter. Finally, Chapman Financial Group LLC bought a new stake in Bruker in the 2nd quarter valued at about $431,000. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.